BioAtla, Inc.
http://bioatla.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioAtla, Inc.
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions
In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.
Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
-
- BioAtla, LLC
- Himalaya Therapeutics SEZC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice